Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA

Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418 · see citing works

Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis

Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O’Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792 · see citing works

Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive

Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,236 · see citing works

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Goor, F. V., Hadidaꝉ, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A. K., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,225 · see citing works

Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report

Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,077 · see citing works

Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screening

Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032 · see citing works

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation

Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M., Dunitz, J., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 803 · see citing works

Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation

Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., et al. (1991) · Nature · doi:10.1038/354526a0 · Cited by 707 · see citing works

Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice

Castellani, C., Cuppens, H., Maçek, M., Cassiman, J. J., Kerem, E., Durie, P. R., Tullis, E. D., Assael, B. M., Bombieri, C., Brown, A., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.009 · Cited by 602 · see citing works

Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening

Pedemonte, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24898 · Cited by 542 · see citing works

Rescue of ΔF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules

Goor, F. V., Straley, K. S., Cao, D., González, J. E., Hadidaꝉ, S., Hazlewood, A., Joubran, J., Knapp, T., Makings, L. R., Miller, M. A., et al. (2006) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00169.2005 · Cited by 515 · see citing works

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

Clancy, J. P., Rowe, S. M., Accurso, F. J., Aitken, M. L., Amin, R. S., Ashlock, M. A., Ballmann, M., Boyle, M., Bronsveld, I., Campbell, P. W., et al. (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200393 · Cited by 514 · see citing works

High treatment burden in adults with cystic fibrosis: challenges to disease self-management

Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.007 · Cited by 498 · see citing works

Chloride channels as drug targets

Verkman, A. S., & Galietta, L. J. V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2780 · Cited by 472 · see citing works

Probing protein structure by limited proteolysis.

Fontana, A., de Laureto, P. P., Spolaore, B., Frare, E., Picotti, P., & Zambonin, M. (2004) · Acta Biochimica Polonica · doi:10.18388/abp.2004_3573 · Cited by 467 · see citing works

Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in α1-AT deficiency

Burrows, J. A. J., Willis, L. K., & Perlmutter, D. H. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1796 · Cited by 428 · see citing works

Peripheral Protein Quality Control Removes Unfolded CFTR from the Plasma Membrane

Okiyoneda, T., Barrière, H., Bagdány, M., Rabeh, W. M., Du, K., Höhfeld, J., Young, J. C., & Lukacs, G. L. (2010) · Science · doi:10.1126/science.1191542 · Cited by 408 · see citing works

Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP.

Lukács, G. L., Mohamed, A., Kartner, N., Chang, X. B., Riordan, J. R., & Grinstein, S. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06954.x · Cited by 397 · see citing works

In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.

Rubenstein, R. C., Egan, M. E., & Zeitlin, P. L. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119788 · Cited by 393 · see citing works

The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells.

Lukacs, G. L., Chang, X. B., Bear, C., Kartner, N., Mohamed, A., Riordan, J. R., & Grinstein, S. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(20)80582-1 · Cited by 387 · see citing works

Phenylalanine-508 mediates a cytoplasmic–membrane domain contact in the CFTR 3D structure crucial to assembly and channel function

Serohijos, A. W. R., Hegedűs, T., Aleksandrov, A. A., He, L., Cui, L., Dokholyan, N. V., & Riordan, J. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800254105 · Cited by 381 · see citing works

The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR

Du, K., Sharma, M., & Lukacs, G. L. (2005) · Nature Structural & Molecular Biology · doi:10.1038/nsmb882 · Cited by 356 · see citing works

A Pilot Clinical Trial of Oral Sodium 4-Phenylbutyrate (Buphenyl) in Δ F508-Homozygous Cystic Fibrosis Patients: Partial Restoration of Nasal Epithelial CFTR Function

Rubenstein, R. C., & Zeitlin, P. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.2.9706088 · Cited by 343 · see citing works

Cystic fibrosis: a disease of vulnerability to airway surface dehydration

Boucher, R. C. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.05.001 · Cited by 271 · see citing works

Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis

Hutt, D. M., Herman, D., Rodrigues, A. P. C., Noël, S., Pilewski, J. M., Matteson, J., Hoch, B., Kellner, W. A., Kelly, J. W., Schmidt, A., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.275 · Cited by 253 · see citing works

Domain Interdependence in the Biosynthetic Assembly of CFTR

Cui, L., Aleksandrov, L., Chang, X.-B., Hou, Y.-X., He, L., Hegedus, T., Gentzsch, M., Aleksandrov, A., Balch, W. E., & Riordan, J. R. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.10.086 · Cited by 216 · see citing works

Cystic Fibrosis: Lessons from the Sweat Gland

Quinton, P. (2007) · Physiology · doi:10.1152/physiol.00041.2006 · Cited by 196 · see citing works

Cystic Fibrosis: A Review of Epidemiology and Pathobiology

Strausbaugh, S. D., & Davis, P. B. (2007) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2007.02.011 · Cited by 184 · see citing works

Abnormal localization of cystic fibrosis transmembrane conductance regulator in primary cultures of cystic fibrosis airway epithelia.

Denning, G. M., Ostedgaard, L. S., & Welsh, M. J. (1992) · The Journal of Cell Biology · doi:10.1083/jcb.118.3.551 · Cited by 171 · see citing works

Side chain and backbone contributions of Phe508 to CFTR folding

Thibodeau, P. H., Brautigam, C. A., Machius, M., & Thomas, P. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb881 · Cited by 169 · see citing works

Limited proteolysis as a probe for arrested conformational maturation of ΔF508 CFTR

Zhang, F., Kartner, N., & Lukács, G. L. (1998) · Nature Structural Biology · doi:10.1038/nsb0398-180 · Cited by 143 · see citing works

Influence of cell background on pharmacological rescue of mutant CFTR

Pedemonte, N., Tomati, V., Sondo, E., & Galietta, L. J. V. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00404.2009 · Cited by 134 · see citing works

Protein Folding Stability Can Determine the Efficiency of Escape from Endoplasmic Reticulum Quality Control

Kowalski, J. M., Parekh, R. N., Mao, J., & Wittrup, K. D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.31.19453 · Cited by 119 · see citing works

α-1-C-Octyl-1-deoxynojirimycin as a pharmacological chaperone for Gaucher disease

Yu, L., Ikeda, K., Kato, A., Adachi, I., Godin, G., Compain, P., Martin, O. R., & Asano, N. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.08.003 · Cited by 106 · see citing works

Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-Phase Clinical Trials

Rowe, S. M., Accurso, F. J., & Clancy, J. P. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200703-043br · Cited by 87 · see citing works

Rescue of ΔF508 and Other Misprocessed CFTR Mutants by a Novel Quinazoline Compound

Loo, T. W., Bartlett, M. C., & Clarke, D. M. (2005) · Molecular Pharmaceutics · doi:10.1021/mp0500521 · Cited by 77 · see citing works

Altered protein folding may be the molecular basis of most cases of cystic fibrosis

Thomas, P., Ko, Y. H., & Pedersen, P. L. (1992) · FEBS Letters · doi:10.1016/0014-5793(92)81399-7 · Cited by 70 · see citing works

The role of cystic fibrosis transmembrane conductance regulator phenylalanine 508 side chain in ion channel gating

Cui, L., Aleksandrov, L. A., Hou, Y., Gentzsch, M., Chen, J.-H., Riordan, J. R., & Aleksandrov, A. A. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.099457 · Cited by 61 · see citing works

Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants

Wang, Y., Loo, T. W., Bartlett, M. C., & Clarke, D. M. (2007) · Biochemical Journal · doi:10.1042/bj20070478 · Cited by 60 · see citing works

Parallel Improvement of Sodium and Chloride Transport Defects by Miglustat (n-Butyldeoxynojyrimicin) in Cystic Fibrosis Epithelial Cells

Noël, S., Wilke, M., Bot, A. G. M., de Jonge, H. R., & Becq, F. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.135582 · Cited by 50 · see citing works

The Role of a Conserved Inter-Transmembrane Domain Interface in Regulating α2a-Adrenergic Receptor Conformational Stability and Cell-Surface Turnover

Wilson, M. H., Highfield, H. A., & Limbird, L. E. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.4.929 · Cited by 50 · see citing works

Destabilizing Mutations Promote Membrane Protein Misfolding

Nagy, J. K., & Sanders, C. R. (2003) · Biochemistry · doi:10.1021/bi035918s · Cited by 46 · see citing works

hERG Channel Trafficking

Ficker, E. K., Dennis, A. T., Kuryshev, Y. A., Wible, B. A., & Brown, A. M. (2005) · Novartis Foundation symposium · doi:10.1002/047002142x.ch6 · Cited by 28 · see citing works

A Pipeline of Therapies for Cystic Fibrosis

Ashlock, M. A., Beall, R. J., Mayer-Hamblett, N., Konstan, M. W., Penland, C. M., Ramsey, B. W., Dalfsen, J. M. V., Wetmore, D. R., & Campbell, P. W. (2009) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0029-1238919 · Cited by 26 · see citing works

Applications of Fluorine in Medicinal Chemistry

Gillis, E. P., Eastman, K. J., Hill, M. D., Donnelly, D. J., & Meanwell, N. A. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00258 · Cited by 3,692 · see citing works

Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design

Meanwell, N. A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01788 · Cited by 2,705 · see citing works

Cystic fibrosis

Elborn, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00576-6 · Cited by 1,710 · see citing works

Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del <i>CFTR</i>

Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622 · see citing works

The future of cystic fibrosis care: a global perspective

Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S. L., Davies, J. C., Burgel, P., Tullis, E., Castaños, C., Castellani, C., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 1,042 · see citing works

Organoids

Zhao, Z., Chen, X., Dowbaj, A. M., Sljukic, A., Bratlie, K., Lin, L., Fong, E. L. S., Balachander, G. M., Chen, Z., Soragni, A., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00174-y · Cited by 1,001 · see citing works

A functional CFTR assay using primary cystic fibrosis intestinal organoids

Dekkers, J. F., Wiegerinck, C. L., de Jonge, H. R., Bronsveld, I., Janssens, H. M., de Winter-de Groot, K. M., Brandsma, A. M., de Jong, N. W. M., Bijvelds, M. J. C., Scholte, B. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3201 · Cited by 999 · see citing works

Cystic fibrosis genetics: from molecular understanding to clinical application

Cutting, G. R. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3849 · Cited by 969 · see citing works

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

Taylor-Cousar, J. L., Munck, A., McKone, E. F., van der Ent, C. K., Moeller, A., Simard, C., Wang, L. T., Ingenito, E. P., McKee, C., Lu, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709846 · Cited by 794 · see citing works

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Keating, D., Marigowda, G., Burr, L., Daines, C., Mall, M. A., McKone, E. F., Ramsey, B. W., Rowe, S. M., Sass, L. A., Tullis, E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807120 · Cited by 726 · see citing works

From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations

Veit, G., Avramescu, R. G., Chiang, A., Houck, S. A., Cai, Z., Peters, K. W., Hong, J. S., Pollard, H. B., Guggino, W. B., Balch, W. E., et al. (2016) · Molecular Biology of the Cell · doi:10.1091/mbc.e14-04-0935 · Cited by 582 · see citing works

Cystic fibrosis

Ratjen, F. A., Bell, S. C., Rowe, S. M., Goss, C. H., Quittner, A. L., & Bush, A. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.10 · Cited by 553 · see citing works

CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine

Lopes‐Pacheco, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01662 · Cited by 570 · see citing works

Tezacaftor–Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis

Rowe, S. M., Daines, C., Ringshausen, F. C., Kerem, E., Wilson, J., Tullis, E., Nair, N., Simard, C., Han, L., Ingenito, E. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709847 · Cited by 522 · see citing works

Complex interplay between autophagy and oxidative stress in the development of pulmonary disease

Ornatowski, W., Lü, Q., Yegambaram, M., Flores, A. G., Zemskov, E. A., Maltepe, E., Fineman, J. R., Wang, T., & Black, S. M. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101679 · Cited by 474 · see citing works

A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial

Boyle, M., Bell, S. C., Konstan, M. W., McColley, S. A., Rowe, S. M., Rietschel, E., Huang, X., Waltz, D. A., Patel, N. R., & Rodman, D. M. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70132-8 · Cited by 451 · see citing works

Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein

Wong, A. P., Bear, C. E., Chin, S., Pasceri, P., Thompson, T., Huan, L., Ratjen, F. A., Ellis, J., & Rossant, J. (2012) · Nature Biotechnology · doi:10.1038/nbt.2328 · Cited by 425 · see citing works

Cholangiocytes derived from human induced pluripotent stem cells for disease modeling and drug validation

Sampaziotis, F., de Brito, M. C., Madrigal, P., Bertero, A., Saeb‐Parsy, K., Soares, F. A. C., Schrumpf, E., Melum, E., Karlsen, T. H., Bradley, J. A., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3275 · Cited by 398 · see citing works

Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect

Villella, V. R., Esposito, S., Bruscia, E. M., Maiuri, M. C., Raia, V., Kroemer, G., & Maiuri, L. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00001 · Cited by 389 · see citing works

Mechanism-based corrector combination restores ΔF508-CFTR folding and function

Okiyoneda, T., Veit, G., Dekkers, J. F., Bagdany, M., Soya, N., Xu, H., Roldan, A., Verkman, A. S., Kurth, M., Simon, A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1253 · Cited by 378 · see citing works

CFTR: folding, misfolding and correcting the ΔF508 conformational defect

Lukacs, G. L., & Verkman, A. S. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.10.003 · Cited by 375 · see citing works

Phenotypic drug discovery: recent successes, lessons learned and new directions

Vincent, F., Nueda, A., Lee, J. L. C., Schenone, M., Prunotto, M., & Mercola, M. A. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00472-w · Cited by 372 · see citing works

Therapies for rare diseases: therapeutic modalities, progress and challenges ahead

Tambuyzer, E., Vandendriessche, B., Austin, C. P., Brooks, P. J., Larsson, K., Miller Needleman, K. I., Valentine, J., Davies, K., Groft, S. C., Preti, R., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0049-9 · Cited by 357 · see citing works

Cleaning Up: ER-Associated Degradation to the Rescue

Brodsky, J. L. (2012) · Cell · doi:10.1016/j.cell.2012.11.012 · Cited by 341 · see citing works

Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function

Goor, F. V., Yu, H., Burton, B., & Hoffman, B. J. (2013) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.06.008 · Cited by 338 · see citing works

VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

Davies, J. C., Moskowitz, S. M., Brown, C., Horsley, A., Mall, M. A., McKone, E. F., Plant, B. J., Prais, D., Ramsey, B. W., Taylor-Cousar, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807119 · Cited by 331 · see citing works

α1-Antitrypsin deficiency

Greene, C. M., Marciniak, S. J., Teckman, J. H., Ferrarotti, I., Brantly, M., Lomas, D. A., Stoller, J. K., & McElvaney, N. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.51 · Cited by 326 · see citing works

Directed differentiation of cholangiocytes from human pluripotent stem cells

Ogawa, M., Ogawa, S., Bear, C. E., Ahmadi, S., Chin, S., Li, B., Grompe, M., Keller, G. M., Kamath, B. M., & Ghanekar, A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3294 · Cited by 318 · see citing works

Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis

Cholon, D. M., Quinney, N. L., Fulcher, M. L., Esther, C. R., Das, J., Dokholyan, N. V., Randell, S. H., Boucher, R. C., & Gentzsch, M. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008680 · Cited by 320 · see citing works

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Potentiator VX-770 (Ivacaftor) Opens the Defective Channel Gate of Mutant CFTR in a Phosphorylation-dependent but ATP-independent Manner

Eckford, P. D. W., Li, C., Ramjeesingh, M., & Bear, C. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.393637 · Cited by 311 · see citing works

Small-Molecule Modulation of Protein Homeostasis.

Burslem, G., & Crews, C. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00077 · Cited by 256 · see citing works

Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial

Ratjen, F. A., Hug, C., Marigowda, G., Tian, S., Huang, X., Stanojevic, S., Milla, C. E., Robinson, P. D., Waltz, D. A., Davies, J. C., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30215-1 · Cited by 297 · see citing works

CFTR modulator theratyping: Current status, gaps and future directions

Clancy, J. P., Cotton, C. U., Donaldson, S. H., Solomon, G. M., VanDevanter, D. R., Boyle, M., Gentzsch, M., Nick, J. A., Illek, B., Wallenburg, J., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.05.004 · Cited by 286 · see citing works

Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study

Konstan, M. W., McKone, E. F., Moss, R. B., Marigowda, G., Tian, S., Waltz, D. A., Huang, X., Lubarsky, B., Rubin, J. L., Millar, S. J., et al. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30427-1 · Cited by 287 · see citing works

Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression

Veit, G., Avramescu, R. G., Perdomo, D., Phuan, P.-W., Bagdany, M., Apaja, P. M., Borot, F., Szollosi, D., Wu, Y.-S., Finkbeiner, W. E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008889 · Cited by 287 · see citing works

VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1

Ren, H. Y., Grove, D. E., Rosa, O. D. L., Houck, S. A., Sopha, P., Goor, F. V., Hoffman, B. J., & Cyr, D. (2013) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-05-0240 · Cited by 281 · see citing works

Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function

Rabeh, W. M., Bossard, F., Xu, H., Okiyoneda, T., Bagdany, M., Mulvihill, C. M., Du, K., di Bernardo, S., Liu, Y., Konermann, L., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.024 · Cited by 280 · see citing works

Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis

Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.014 · Cited by 272 · see citing works

Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences

Mendoza, J. L., Schmidt, A., Li, Q., Nuvaga, E., Barrett, T., Bridges, R. J., Feranchak, A. P., Brautigam, C. A., & Thomas, P. J. (2012) · Cell · doi:10.1016/j.cell.2011.11.023 · Cited by 261 · see citing works

CFTR: cystic fibrosis and beyond

Mall, M. A., & Hartl, D. (2014) · European Respiratory Journal · doi:10.1183/09031936.00228013 · Cited by 257 · see citing works

Structural identification of a hotspot on CFTR for potentiation

Liu, F., Zhang, Z., Levit, A., Levring, J., Touhara, K. K., Shoichet, B. K., & Chen, J. (2019) · Science · doi:10.1126/science.aaw7611 · Cited by 259 · see citing works

Cystic fibrosis: current therapeutic targets and future approaches

Rafeeq, M. M., & Murad, H. A. S. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1193-9 · Cited by 254 · see citing works

Folding and Misfolding of Human Membrane Proteins in Health and Disease: From Single Molecules to Cellular Proteostasis

Marinko, J. T., Huang, H., Penn, W. D., Capra, J. A., Schlebach, J. P., & Sanders, C. R. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00532 · Cited by 249 · see citing works

Structure, Gating, and Regulation of the CFTR Anion Channel

Csanády, L., Vergani, P., & Gadsby, D. C. (2018) · Physiological Reviews · doi:10.1152/physrev.00007.2018 · Cited by 246 · see citing works

A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect

Boyle, M., & Boeck, K. D. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(12)70057-7 · Cited by 243 · see citing works

Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications

Mall, M. A., Mayer-Hamblett, N., & Rowe, S. M. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201910-1943so · Cited by 229 · see citing works

Do you know the sex of your cells?

Shah, K., McCormack, C. E., & Bradbury, N. A. (2014) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00281.2013 · Cited by 219 · see citing works

Cystic fibrosis

Mall, M. A., Burgel, P., Castellani, C., Davies, J. C., Salathe, M. A., & Taylor‐Cousar, J. L. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00538-6 · Cited by 223 · see citing works

Developing predictive assays: The phenotypic screening “rule of 3”

Vincent, F., Loria, P. M., Pregel, M. J., Stanton, R. V., Kitching, L., Nocka, K. H., Doyonnas, R., Steppan, C. M., Gilbert, A. M., Schroeter, T., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab1201 · Cited by 204 · see citing works

Mechanism of CFTR correction by type I folding correctors

Fiedorczuk, K., & Chen, J. (2022) · Cell · doi:10.1016/j.cell.2021.12.009 · Cited by 195 · see citing works

In vivo editing of lung stem cells for durable gene correction in mice

Sun, Y., Chatterjee, S., Lian, X., Traylor, Z., Sattiraju, S. R., Xiao, Y., Dilliard, S. A., Sung, Y., Kim, M., Lee, S. M., et al. (2024) · Science · doi:10.1126/science.adk9428 · Cited by 185 · see citing works

CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis

Lopes‐Pacheco, M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00275 · Cited by 183 · see citing works

Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators

Fiedorczuk, K., & Chen, J. (2022) · Science · doi:10.1126/science.ade2216 · Cited by 176 · see citing works

CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis

Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01609-4 · Cited by 173 · see citing works

New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls

Bell, S. C., Boeck, K. D., & Amaral, M. D. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.06.005 · Cited by 169 · see citing works

Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR

Milla, C. E., Ratjen, F. A., Marigowda, G., Liu, F., Waltz, D. A., & Rosenfeld, M. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201608-1754oc · Cited by 170 · see citing works

Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis

Elborn, J. S., Ramsey, B. W., Boyle, M., Konstan, M. W., Huang, X., Marigowda, G., Waltz, D. A., & Wainwright, C. E. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(16)30121-7 · Cited by 166 · see citing works

Biophysical and Mechanistic Models for Disease-Causing Protein Variants

Stein, A., Fowler, D. M., Hartmann‐Petersen, R., & Lindorff‐Larsen, K. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.01.003 · Cited by 165 · see citing works

Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction

Farinha, C. M., King-Underwood, J., Sousa, M., Correia, A. R., Henriques, B. J., Roxo‐Rosa, M., Paula, A. C. D., Williams, J. P., Hirst, S., Gomes, C. M., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.004 · Cited by 164 · see citing works

Correction of CFTR function in nasal epithelial cells from cystic fibrosis patients predicts improvement of respiratory function by CFTR modulators

Pranke, I. M., Hatton, A., Simonin, J., Jais, J. P., Le Pimpec-Barthes, F., Carsin, A., Bonnette, P., Fayon, M., Stremler-Le Bel, N., Grenet, D., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07504-1 · Cited by 161 · see citing works

Air−Liquid Interface Cultures of the Healthy and Diseased Human Respiratory Tract: Promises, Challenges, and Future Directions

Baldassi, D., Gabold, B., & Merkel, O. M. (2021) · Advanced NanoBiomed Research · doi:10.1002/anbr.202000111 · Cited by 163 · see citing works

Glucose-induced electrical activities and insulin secretion in pancreatic islet β-cells are modulated by CFTR

Guo, J. H., Chen, H., Ruan, Y. C., Zhang, X. L., Zhang, X. H., Fok, K. L., Tsang, L. L., Yu, M. K., Huang, W. Q., Sun, X., et al. (2014) · Nature Communications · doi:10.1038/ncomms5420 · Cited by 157 · see citing works

International consensus statements on early chronic Pancreatitis. Recommendations from the working group for the international consensus guidelines for chronic pancreatitis in collaboration with The International Association of Pancreatology, American Pancreatic Association, Japan Pancreas Society, PancreasFest Working Group and European Pancreatic Club

Whitcomb, D. C., Shimosegawa, T., Chari, S. T., Forsmark, C. E., Frulloni, L., Garg, P. K., Hegyi, P., Hirooka, Y., Irisawa, A., Ishikawa, T., et al. (2018) · Pancreatology · doi:10.1016/j.pan.2018.05.008 · Cited by 158 · see citing works

Synthetic Aminoglycosides Efficiently Suppress Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations and Are Enhanced by Ivacaftor

Xue, X., Mutyam, V., Tang, L., Biswas, S., Du, M., Jackson, L. A., Dai, Y., Белахов, В. В., Shalev, M., Chen, F., et al. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0282oc · Cited by 152 · see citing works

New and emerging targeted therapies for cystic fibrosis

Quon, B. S., & Rowe, S. M. (2016) · BMJ · doi:10.1136/bmj.i859 · Cited by 148 · see citing works

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation

Stefano, D. D., Villella, V. R., Esposito, S., Tosco, A., Sepe, A. O., Gregorio, F. D., Salvadori, L., Grassia, R., Leone, C. A., Rosa, G. D., et al. (2014) · Autophagy · doi:10.4161/15548627.2014.973737 · Cited by 149 · see citing works

Targeting ion channels in cystic fibrosis

Mall, M. A., & Galietta, L. J. V. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.06.002 · Cited by 147 · see citing works

Chaperoning G Protein-Coupled Receptors: From Cell Biology to Therapeutics

Tao, Y., & Conn, P. M. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1121 · Cited by 146 · see citing works

Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells

Valley, H. C., Bukis, K., Bell, A., Cheng, Y., Wong, E., Jordan, N. J., Allaire, N., Sivachenko, A., Liang, F., Bihler, H. J., et al. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.12.001 · Cited by 141 · see citing works

Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein

He, L., Kota, P. B., Aleksandrov, A. A., Cui, L., Jensen, T., Dokholyan, N. V., & Riordan, J. R. (2012) · The FASEB Journal · doi:10.1096/fj.12-216119 · Cited by 139 · see citing works

Chaperoning Endoplasmic Reticulum–Associated Degradation (ERAD) and Protein Conformational DiseasesPreprint

Needham, P. G., Guerriero, C. J., & Brodsky, J. L. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033928 · Cited by 139 · see citing works

Digital droplet PCR on disk

Schuler, F., Trotter, M. J., Geltman, M., Schwemmer, F., Wadle, S., Domínguez‐Garrido, E., López, M., Acedo, C. C., Santibáñez, P., von Stetten, F., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc01068c · Cited by 138 · see citing works

Structural mechanisms of CFTR function and dysfunction

Hwang, T., Yeh, J., Zhang, J., Yu, Y.-C., Yeh, H., & DeStefano, S. (2018) · The Journal of General Physiology · doi:10.1085/jgp.201711946 · Cited by 131 · see citing works

Structure-guided combination therapy to potently improve the function of mutant CFTRs

Veit, G., Xu, H., Dreano, E., Avramescu, R. G., Bagdany, M., Beitel, L. K., Roldan, A., Hancock, M. A., Lay, C., Li, W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0200-x · Cited by 134 · see citing works

Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study

McNamara, J., McColley, S. A., Marigowda, G., Liu, F., Tian, S., Owen, C. A., Stiles, D., Li, C., Waltz, D. A., Wang, L. T., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30460-0 · Cited by 136 · see citing works

High-Efficiency, Selection-free Gene Repair in Airway Stem Cells from Cystic Fibrosis Patients Rescues CFTR Function in Differentiated Epithelia

Vaidyanathan, S., Salahudeen, A. A., Sellers, Z. M., Bravo, D. T., Choi, S. S., Batish, A., Le, W., Baik, R., Sean de la, O., Kaushik, M. P., et al. (2019) · Cell stem cell · doi:10.1016/j.stem.2019.11.002 · Cited by 135 · see citing works

Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model

Mehta, A. K., Ramachandra, C. J. A., Singh, P., Chitre, A., Lua, C. H., Mura, M., Crotti, L., Wong, P., Schwartz, P. J., Gnecchi, M., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx394 · Cited by 133 · see citing works

Small-Molecule Structure Correctors Target Abnormal Protein Structure and Function: Structure Corrector Rescue of Apolipoprotein E4–Associated Neuropathology: Miniperspective

Mahley, R. W., & Huang, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3008618 · Cited by 132 · see citing works

Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward

Cooney, A. L., McCray, P., & Sinn, P. (2018) · Genes · doi:10.3390/genes9110538 · Cited by 118 · see citing works

Chitosan in Non-Viral Gene Delivery: Role of Structure, Characterization Methods, and Insights in Cancer and Rare Diseases Therapies

Santos-Carballal, B., Fernández, E. F., & Goycoolea, F. M. (2018) · Polymers · doi:10.3390/polym10040444 · Cited by 132 · see citing works

A small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion

Sharma, J., Du, M., Wong, E., Mutyam, V., Li, Y., Chen, J., Wangen, J. R., Thrasher, K., Fu, L., Peng, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24575-x · Cited by 129 · see citing works

Genetics of cystic fibrosis: CFTR mutation classifications toward genotype-based CF therapies

Fanen, P., Wohlhuter‐Haddad, A., & Hinzpeter, A. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.02.023 · Cited by 125 · see citing works

Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients

Boj, S. F., Vonk, A. M., Statia, M., Su, J., Dekkers, J. F., Vries, R., Beekman, J. M., & Clevers, H. C. (2017) · Journal of Visualized Experiments · doi:10.3791/55159 · Cited by 132 · see citing works

Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine

Pranke, I. M., Golec, A., Hinzpeter, A., Edelman, A., & Sermet‐Gaudelus, I. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00121 · Cited by 121 · see citing works

Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis

Derichs, N. (2013) · European Respiratory Review · doi:10.1183/09059180.00008412 · Cited by 122 · see citing works

Barriers to inhaled gene therapy of obstructive lung diseases: A review

Kim, N., Duncan, G. A., Hanes, J. S., & Suk, J. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.031 · Cited by 118 · see citing works

Effects of Lumacaftor–Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis

Graeber, S. Y., Dopfer, C., Naehrlich, L., Gyulumyan, L., Scheuermann, H., Hirtz, S., Wege, S., Mairbäurl, H., Dorda, M., Hyde, R., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201710-1983oc · Cited by 117 · see citing works

Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases

Tao, Y., & Conn, P. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00029.2016 · Cited by 115 · see citing works

Recurrent Acute Pancreatitis

Guda, N. M., Muddana, V. N., Whitcomb, D. C., Lévy, P., Garg, P. K., Coté, G. A., Uç, A., Varadarajulu, S. S., Vege, S. S., Chari, S. T., et al. (2018) · Pancreas · doi:10.1097/mpa.0000000000001053 · Cited by 116 · see citing works

Anion carriers as potential treatments for cystic fibrosis: transport in cystic fibrosis cells, and additivity to channel-targeting drugs

Li, H., Valkenier, H., Thorne, A. G., Dias, C. M., Cooper, J. A., Kieffer, M., Busschaert, N., Gale, P. A., Sheppard, D. N., & Davis, A. P. (2019) · Chemical Science · doi:10.1039/c9sc04242c · Cited by 144 · see citing works

Suppression of premature termination codons as a therapeutic approach

Keeling, K. M., Wang, D., Conard, S. E., & Bedwell, D. M. (2012) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2012.694846 · Cited by 111 · see citing works

Corrector VX-809 stabilizes the first transmembrane domain of CFTR

Loo, T. W., Bartlett, M. C., & Clarke, D. M. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.028 · Cited by 110 · see citing works

Protein damage, ageing and age-related diseases

Kriško, A., & Radman, M. (2019) · Open Biology · doi:10.1098/rsob.180249 · Cited by 108 · see citing works

Brushed nasal epithelial cells are a surrogate for bronchial epithelial CFTR studies

Brewington, J. J., Filbrandt, E. T., LaRosa, F. J., Moncivaiz, J. D., Ostmann, A. J., Strecker, L. M., & Clancy, J. P. (2018) · JCI Insight · doi:10.1172/jci.insight.99385 · Cited by 106 · see citing works

From the endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking

Farinha, C. M., & Canato, S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2387-7 · Cited by 108 · see citing works

Drug discovery and development for rare genetic disorders

Sun, W., Zheng, W., & Simeonov, A. (2017) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.38326 · Cited by 107 · see citing works

Novel personalized therapies for cystic fibrosis: treating the basic defect in all patients

Amaral, M. D. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12314 · Cited by 107 · see citing works

Pharmacological Chaperones: Design and Development of New Therapeutic Strategies for the Treatment of Conformational Diseases

Convertino, M., Das, J., & Dokholyan, N. V. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00195 · Cited by 114 · see citing works

Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two<i>F508del</i>alleles

Taylor-Cousar, J. L., Mall, M. A., Ramsey, B. W., McKone, E. F., Tullis, E., Marigowda, G., McKee, C. M., Waltz, D., Moskowitz, S. M., Savage, J., et al. (2019) · ERJ Open Research · doi:10.1183/23120541.00082-2019 · Cited by 105 · see citing works

Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis

Romani, L. R., Oikonomou, V., Moretti, S., Iannitti, R. G., D’Adamo, M. C., Villella, V. R., Pariano, M., Sforna, L., Borghi, M., Bellet, M. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4305 · Cited by 105 · see citing works

Increased efficacy of VX ‐809 in different cellular systems results from an early stabilization effect of F508del‐ CFTR

Farinha, C. M., Sousa, M., Canato, S., Schmidt, A., Uliyakina, I., & Amaral, M. D. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.152 · Cited by 43 · see citing works

Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function

Arora, K., & Naren, A. P. (2016) · Current Drug Targets · doi:10.2174/1389450117666151209114343 · Cited by 11 · see citing works

Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors

Amico, G., Brandas, C., Morán, Ó., & Baroni, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215463 · Cited by 26 · see citing works

Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment

Capurro, V., Tomati, V., Sondo, E., Renda, M., Borrelli, A., Pastorino, C., Guidone, D., Venturini, A., Giraudo, A., Bertozzi, S. M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105262 · Cited by 72 · see citing works

Revertants, Low Temperature, and Correctors Reveal the Mechanism of F508del-CFTR Rescue by VX-809 and Suggest Multiple Agents for Full Correction

Farinha, C. M., King-Underwood, J., Sousa, M., Correia, A. R., Henriques, B. J., Roxo‐Rosa, M., Paula, A. C. D., Williams, J. P., Hirst, S., Gomes, C. M., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.06.004 · Cited by 164 · see citing works